Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23,994 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial.
Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Shi L, et al. Among authors: xie wf, xie y. EBioMedicine. 2022 Jan;75:103789. doi: 10.1016/j.ebiom.2021.103789. Epub 2021 Dec 25. EBioMedicine. 2022. PMID: 34963099 Free PMC article. Clinical Trial.
HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients.
Xu R, Zhang JY, Tu B, Xu Z, Huang HH, Huang L, Jiao YM, Yang T, Zhang C, Qin EQ, Jiang TJ, Xie YB, Li YY, Jin L, Zhou CB, Shi M, Guo M, Ai HS, Zhang L, Wang FS. Xu R, et al. Signal Transduct Target Ther. 2021 May 7;6(1):174. doi: 10.1038/s41392-021-00550-2. Signal Transduct Target Ther. 2021. PMID: 33958574 Free PMC article. Clinical Trial.
Mesenchymal stem cell therapy for severe COVID-19.
Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Shi L, et al. Among authors: xie y. Signal Transduct Target Ther. 2021 Sep 8;6(1):339. doi: 10.1038/s41392-021-00754-6. Signal Transduct Target Ther. 2021. PMID: 34497264 Free PMC article. Review.
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS. Meng F, et al. Among authors: xie y. Hepatol Int. 2021 Dec;15(6):1402-1412. doi: 10.1007/s12072-021-10250-2. Epub 2021 Nov 30. Hepatol Int. 2021. PMID: 34850325 Free PMC article. Clinical Trial.
Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, Shi M, Li Y, Xie Y, Liu LM, Zhou CB, Chua A, Ho ZZ, Luan J, Zhao J, Li J, Wai LE, Koh S, Wang T, Bertoletti A, Wang FS. Tan AT, et al. Among authors: xie y. Hepatol Commun. 2022 Apr;6(4):841-854. doi: 10.1002/hep4.1857. Epub 2021 Dec 21. Hepatol Commun. 2022. PMID: 34935312 Free PMC article.
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.
Liu HH, Xie Y, Yang BP, Wen HY, Yang PH, Lu JE, Liu Y, Chen X, Qu MM, Zhang Y, Hong WG, Li YG, Fu J, Wang FS. Liu HH, et al. Among authors: xie y. Signal Transduct Target Ther. 2024 May 13;9(1):129. doi: 10.1038/s41392-024-01846-9. Signal Transduct Target Ther. 2024. PMID: 38740763 Free PMC article.
23,994 results
You have reached the last available page of results. Please see the User Guide for more information.